This chapter reviews the role of benzodiazepines (BZs) in the treatment of anxiety disorders, specifically panic disorder with or without agoraphobia, generalized anxiety disorder, and social anxiety disorder (social phobia). BZs pharmacology, classification, efficacy, adverse effects, withdrawal symptoms, possible dependence, and abuse; their positioning among pharmacological treatment; and guidance on how to use them are discussed.
- Panic disorder
- Generalized anxiety disorder
- Social phobia
This is a preview of subscription content, access via your institution.
Bowes HA. The role of Librium in an out-patient psychiatric setting. Dis Nerv Syst. 1960;21(Suppl 3):20–2.
Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72:136–42.
Rickels K. Should benzodiazepines be replaced by antidepressants in the treatment of anxiety disorders? Facts of fiction? Psychother Psychosom. 2013;82:351–2.
Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. 2013;82:355–62.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy: Current status of benzodiazepines (first of two parts). N Engl J Med. 1983;309:354–8.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, D.C.: American Psychiatric Association; 1980.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Revised. Washington, D.C., American Psychiatric Association, 1987.
Noyes R Jr, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, et al. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry. 1984;41:287–92.
Ballenger JC, Burrows GD, DuPont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45:413–22.
Noyes R Jr, DuPont RL Jr, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry. 1988;45:423–8.
Rifkin A, Pecknold JC, Swinson RP, Ballenger JC, Burrows GD, Noyes R, et al. Sequence of improvement in agoraphobia with panic attacks. J Psychiatr Res. 1990;24:1–8.
Klein DF. Anxiety reconceptualized. In: Klein DF, Raskin J, editors. Anxiety: new research and changing concepts. New York: Raven Press; 1981. p. 235–63.
Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, et al. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol. 1989;9:22–7.
Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry. 1990;23:90–3.
Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry. 1989;50:418–23.
Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991;52:69–76.
Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine and placebo. Cross-National Collaborative Panic Study. Second Phase Investigators. (No authors listed) Br J Psychiatry. 1992;160:191–202.
Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry. 1993;50:51–60.
Nardi AE, Valenca AM, Freire RC, Mochcovitch MD, Amrein R, Sardinha A, et al. Psychopharmacotherapy of panic disorder: 8 week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res. 2011;44:366–73.
Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, et al. A randomized naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012;32:120–6.
Freire RC, Amrein R, Mochcovitch MD, Dias GP, Machado S, Versiani M, et al. A 6-year posttreatment follow-up of panic disorder patients: treatment with clonazepam predicts lower recurrence than treatment with paroxetine. J Clin Psychopharmacol. 2017;37:429–34.
Chouinard G, Annable L, Fontaine R, Solyom L. Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled studt. Pharmacopsychiatry. 1982;77:229–33.
Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol. 1984;4:125–9.
Fontaine M, Mercier P, Beaudry P, Annable L, Chouinard G. Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurements of drug plasma concentrations. Acta Psychiatr Scand. 1986;74:451–8.
Spenard J, Caille G, de Montigny C, Vezina M, Oulette J, Lariviere L, et al. Placebo-controlled comparative study of the anxiolytic activity and pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. Biopharm Drug Dispos. 1988;9:457–64.
Kragh-Sorensen P, Holm P, Fynboe C, Schaumburg E, Andersen B, Bech P, et al. Bromazepam in generalized anxiety. Randomized, multi-practice comparisons with both chlorprothixene and placebo. Psychopharmacology (Berl). 1990;100:383–6.
Bertolino A, Mastucci E, Porro V, Corfiati L, Palermo M, Ecari U, et al. Etizolam in the treatment of generalized anxiety disorder: a controlled clinical trial. J Int Med Res. 1989;17:455–60.
Berlin I, Colombo G, Furlanut M, Benetello P. Double-blind placebo cross-over study of long-acting (chlordesmethyldiazepam) versus short-acting (lorazepam) benzodiazepines in generalized anxiety disorders. Int J Clin Pharmacol Res. 1989;9:203–8.
Wilcox CS, Ryan PJ, Morrissey JL, Cohn JB, DeFrancisco DF, Linden RD, Heiser JF. A fixed-dose study of adinazolam-SR tablets in generalized anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:979–93.
Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1982;43:103–8.
Jacobson AF, Dominguez RE, Goldstein BJ, Steinbook RM. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy. 1985;5:290–6.
Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl). 1991;105:428–32.
Rickels K, DeMartinis N, Aufdembrinke B. A double-blind, placebo-controlled trial of abercanil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol. 2000;20:12–8.
Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884–95.
Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalized anxiety disorder. Eur Psychiatry. 2003;18:182–7.
Feltner DE, Harness J, Brock J, Sambunaris A, Cappelleri JC, Morlock R. Clinical evaluation of daily assessment of symptoms-anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder. CNS Neurosci Ther. 2009;15:12–8.
Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother. 2018;19:883–94.
Reinhold JA, Rickels K. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother. 2015;16:1669–81.
Lydiard RB, Laraia MT, Howell EF, Ballenger JC. Alprazolam in the treatment of social phobia. J Clin Psychiatry. 1988;49:17–9.
Reich J, Yates W. A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry. 1988;145:590–4.
Reiter SR, Pollack MH, Rosenbaum JF, Cohen LS. Clonazepam for the treatment of social phobia. J Clin Psychiatry. 1990;51:470–2.
Ontiveros A, Fontaine R. Social phobia and clonazepam. Can J Psychiatry. 1990;35:439–41.
Munjack DJ, Baltazar PJ, Bohn PG, Cabe DD, Appleton AA. Clonazepam in the treatment of social phobia: a pilot study. J Clin Psychiatry. 1990;51(Suppl):35–40.
Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13:423–8.
Otto MW, Pollack MH, Gould RA, Worthington JJ 3rd, McArdle ET, Rosenbaum JF. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000;14:345–58.
Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry. 2004;65:244–8.
Hooper JF. House calls and alprazolam for agoraphobia. Am Fam Physician. 1991;44:1132–4.
Hollenhorst J, Munte S, Friedrich L, Heine J, Leuwer M, Becker H, et al. Using intranasal midazolam spray to prevent claustrophobia. AJR Am J Roentgenol. 2001;176:865–8.
Haefely W. Biological basis of drug-induced tolerance, rebound, and dependence: contribution of recent research on benzodiazepines. Pharmacopsychiatry. 1986;19:353–61.
O’Brien CP. Response to commentaries. Addiction. 2011;106:895–7.
Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder: 2.5 year naturalistic follow-up study. Arch Gen Psychiatry. 1989;46:993–9.
Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol. 1993;13:257–63.
Worthington JJ, Pollack MH, Otto MW, McLean RYS, Moroz G, Rosenbaum JF. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull. 1998;34:199–205.
Soumerai SB, Simoni-Wastila L, Singer C, Mah C, Gao X, Salzman C, et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv. 2003;54:1006–11.
Nardi AE, Valença AM, Freire RC, Amrein R, Sardinha A, Levitan MN, et al. Randomized, open naturalistic, acute treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2011;31:259–61.
Tyrer P, Rutherford D, Huggett T. Benzodiazepine withdrawal symptoms and propranolol. Lancet. 1981;317:520–2.
Starcevic V. Benzodiazepines for anxiety disorders: maximising the benefits and minimising the risks. Adv Psychiatr Treat. 2012;18:250–8.
Balter MB, Ban TA, Uhlenhuth EH. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: I. Current concerns. Hum Psychopharmacol Clin Exp. 1993;8:253–61.
Uhlenhuth EH, Balter MB, Ban TA, Yang KMS. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. J Clin Psychopharmacol. 1999;19(Suppl 2):23S–9S.
Labelle A, Lapierre YD. Anxiety disorders. Part 2: pharmacotherapy with benzodiazepines. Can Fam Physician. 1993;39:2205–08, 2011–13.
Starcevic V. Issues in the pharmacological treatment of anxiety disorders. Australas Psychiatry. 2005;13:371–4.
Bühler K-E. Euphoria, ecstasy, inebriation, abuse, dependence, and addiction: a conceptual analysis. Med Health Care Philos. 2005;8:79–87.
Lader M. Benzodiazepines revisited – will we ever learn? Addiction. 2011;106:2086–109.
Tyrer P. Why benzodiazepines are not going away. Commentary on… benzodiazepines for anxiety disorders. Adv Psychiatr Treat. 2012;18:259–62.
Dell’Osso B, Albert U, Atti AR, Carmassi C, Carra G, Cosci F, et al. Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat. 2015;11:1885–909.
The American Psychiatric Association Task Forcew on Benzodiazepine Dependency. Benzodiazepine dependence, toxicity, and abuse. The Task Force Report of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association; 1990.
Shaffer HJ. Strange bedfellows: a critical view of pathological gambling and addiction. Addiction. 1999;94:1445–8.
Potenza MN. Should addictive disorders include non-substance-related conditions? Addiction. 2006;101(Suppl 1):142–51.
American Society of Addiction Medicine. Public Policy Statement: Definition of Addiction. 2011. Available at: https://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2011/12/15/the-definition-of-addiction
O’Brien CP, Volkow N, Li T-K. What’s in a word? Addiction versus dependence in DSM-V. Am J Psychiatry. 2006;163:764–5.
Starcevic V. The importance of distinguishing between dependence and addiction in the context of long-term benzodiazepine use. Aust NZ J Psychiatry. 2016;50:1111–2.
Salzman C, Fisher J, Nobel K, Glassman R, Wolfson A, Kelley M. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry. 1992;7:89–93.
Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169:1952–60.
Wagner AK, Ross-Degnan D, Gurwitz JH, Zhang F, Gilden DB, Cosler L, et al. Effect of New York state regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med. 2007;146:96–103.
Bierman EJM, Comijs HC, Gundy CM, Sonnenberg C, Jonker C, Beekman AT. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatr Psychiatry. 2007;22:1194–200.
Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66(Suppl 2):9–13.
Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI. Benzodiazepine use and aggressive behaviour: a systematic review. Aust NZ J Psychiatry. 2014;48:1096–114.
Balon R. Benzodiazepines revisited. Psychother Psychosom. 2013;82:353–4.
Starcevic V. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Exp Rev Neurotherap. 2014;14:1275–86.
Balon R, Fava GA, Rickels K. Need for a realistic appraisal of benzodiazepines. World Psychiatry. 2015;14:243–4.
Balon R, Chouinard G, Cosci F, Dubovsky SL, Fava GA, Freire RC, et al. International task force on benzodiazepines. Psychother Psychosom. 2018;87:193–4.
Starcevic V. Will the RANZCP clinical practice guidelines for the treatment of anxiety disorders assist in making adequate treatment decisions for panic disorder? Aust NZ J Psychiatry. 2019;53:362–3.
Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. J Clin Psychiatry. 1997;58:555–61.
Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry. 2003;160:1432–8.
Pollack MH, Van Ameringen M, Simon NM, Worthington JW, Hoge EA, Keshaviah A, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014;171:44–53.
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84:72–81.
Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom. 2018;87:195–203.
Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 2012;107:900–8.
Starcevic V, Brakoulias V, Viswasam K, Berle D. Inconsistent portrayal of medication dependence, withdrawal and discontinuation symptoms in treatment guidelines for anxiety disorders. Psychother Psychosom. 2015;84:379–80.
Starcevic V. Is the need for medications with calming effects ever going to disappear? Aust NZ J Psychiatry. 2013;47:971.
Rosen CS, Greenbaum MA, Schnurr PP, Holmes TH, Brennan PL, Friedman MJ. Do benzodiazepines reduce the effectiveness of exposure therapy for posttraumatic stress disorder? J Clin Psychiatry. 2013;74:1241–8.
Posternak MA, Mueller TI. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am J Addict. 2001;10:48–68.
Mueller TI, Pagano ME, Rodriguez BF, Bruce SE, Stout RL, Keller MB. Long-term use of benzodiazepines in participants with comorbid anxiety and alcohol use disorders. Alcohol Clin Exp Res. 2005;29:1411–8.
Benasi G, Guidi J, Offidani E, Balon R, Rickels K, Fava GA. Benzodiazepines as a monotherapy in depressive disorders: a systematic review. Psychother Psychosom. 2018;87:65–74.
Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry. 2001;58:681–6.
Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003;17:276–82.
Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328:1398–405.
Hoehn-Saric R, McLeod DR, Zimerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 1988;49:293–301.
Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2002;63(Suppl 14):9–16.
Editors and Affiliations
Rights and permissions
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Balon, R., Starcevic, V. (2020). Role of Benzodiazepines in Anxiety Disorders. In: Kim, YK. (eds) Anxiety Disorders. Advances in Experimental Medicine and Biology, vol 1191. Springer, Singapore. https://doi.org/10.1007/978-981-32-9705-0_20
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9704-3
Online ISBN: 978-981-32-9705-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)